Thymosin beta-4 eye drops improved all measures of dry eye in mice within 7 days by blocking the NF-κB inflammatory pathway, restoring goblet cells, and reducing cell death on the eye surface.
All clinical parameters improved in 7 daysBoth 0.05% and 0.1% Tβ4 eye drops improved tear volume, corneal health, goblet cell counts, and reduced inflammation after just 7 days of treatment in dry eye mice
What the researchers found
Thymosin beta-4 (Tβ4) eye drops at both 0.05% and 0.1% concentrations improved all clinical measures of dry eye disease in mice within 7 days. The peptide increased tear production, reduced corneal staining (a measure of surface damage), restored goblet cells in the conjunctiva (which produce the protective mucus layer), and reduced cell death in the cornea and conjunctiva.
The mechanism was anti-inflammatory: Tβ4 reduced inflammatory cytokine levels and CD4+ T cell infiltration by blocking NF-κB activation — the master inflammatory switch. Both doses were effective.
Why it matters
Dry eye disease affects hundreds of millions of people globally and current treatments are limited. Tβ4 is unique because it simultaneously addresses multiple aspects of dry eye: it reduces inflammation, protects cells from death, and restores the goblet cells that produce the eye's protective mucus coating. This multi-mechanism approach could be more effective than current single-target therapies like cyclosporine or lifitegrast.
The numbers in context
0.05% and 0.1% rhTβ4 · 7-day treatment · increased tear volume · reduced corneal staining · increased goblet cells · reduced CD4+ T cells · blocked NF-κB
How the study worked
Dry eye was induced in mice using benzalkonium chloride (BAC), a chemical preservative that damages the ocular surface. Mice received eye drops containing 0.05% or 0.1% recombinant human Tβ4 for 7 days. Researchers measured tear volume, corneal staining scores, goblet cell counts (PAS staining), CD4+ T cell infiltration (immunohistochemistry), cell death (TUNEL assay), inflammatory cytokines (qRT-PCR and ELISA), and NF-κB activation.
Who was studied
Mice with benzalkonium chloride-induced dry eye disease
What this study cannot tell us
Mouse model only — human dry eye is a chronic condition with different underlying causes than chemically-induced mouse DED. The 7-day treatment period is short. No comparison to existing dry eye treatments (cyclosporine, lifitegrast). The BAC model may not capture all aspects of human dry eye. Specific statistical values and sample sizes are not provided in the abstract.
How to read the evidence
This is a well-conducted animal study with multiple outcome measures and mechanistic investigation. However, it's limited to a chemically-induced mouse model of dry eye, and results may not translate directly to human chronic dry eye. The evidence is early-stage.
When this study was published
Published in 2022. Tβ4 eye drops (RGN-259) have been in clinical development for dry eye. This animal study provides mechanistic support for the ongoing clinical program. Check for updated clinical trial results.
The bigger picture
Tβ4 has a long history in wound healing research, and its application to dry eye leverages its dual anti-inflammatory and tissue-repair properties. The dry eye drug market is worth billions and growing, but patient satisfaction remains low. A peptide that addresses both the inflammatory cause and the tissue damage of dry eye could fill a significant unmet need. RGN-259, a Tβ4-based eye drop, has been in clinical trials for dry eye, making this animal data part of a broader development program.
Questions still open
- How does Tβ4 compare head-to-head with cyclosporine (Restasis) or lifitegrast (Xiidra) in treating dry eye?
- Are the effects of Tβ4 eye drops sustained after treatment is stopped, or does dry eye return?
- What is the optimal dosing frequency for Tβ4 eye drops in chronic dry eye management?
Common questions
What is thymosin beta-4 and why would it help dry eye?
Are thymosin beta-4 eye drops available for patients yet?
Read the original research
Recombinant Human Thymosin β4 (rhTβ4) Modulates the Anti-Inflammatory Responses to Alleviate Benzalkonium Chloride (BAC)-Induced Dry Eye Disease.
International journal of molecular sciences, 23(10)
Citation
Zhai, Yanfang; Zheng, Xiaoxiang; Mao, Yunyun; Li, Kai; Liu, Yanhong; Gao, Yuemei; Zhao, Mengsu; Yang, Rui; Yu, Rui; Chen, Wei. (2022). Recombinant Human Thymosin β4 (rhTβ4) Modulates the Anti-Inflammatory Responses to Alleviate Benzalkonium Chloride (BAC)-Induced Dry Eye Disease.. International journal of molecular sciences, 23(10). https://doi.org/10.3390/ijms23105458